Human Cardiovascular Progenitor Cell Isolation via KDR Marker
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the ability to effectively identify and isolate human cardiovascular progenitor cells, which are crucial for cardiac development and tissue repair, due to the absence of a reliable marker for human cardiovascular progenitor cells.
Innovation Solution
Characterization of human cardiovascular progenitor cells by the presence of the KDR cell surface marker and absence of C-KIT, with methods involving culturing embryoid bodies in specific growth factors like activin, BMP, and VEGF to enrich and differentiate these cells into cardiomyocytes, endothelial cells, and vascular smooth muscle cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to identify and isolate human cardiovascular progenitor cells, then the process is simple, but the ability to effectively identify and isolate these cells is insufficient due to lack of reliable markers
Solution Approach 1:
The patent applies fluorescently labeled antibodies that bind to specific cell surface markers (KDR, C-KIT, CD34) on cardiovascular progenitor cells. These fluorescent labels enable visual detection and sorting of the progenitor cells through flow cytometry, transforming the invisible molecular markers into detectable fluorescent signals that precisely identify the target cell population.
2Manufacturing precision
If no specific markers are used for cell isolation, then the isolation process is straightforward, but the purity and enrichment of cardiovascular progenitor cells cannot be achieved
Solution Approach 1:
The patent employs flow cytometry to detect fluorescently labeled cell surface markers and provides real-time feedback for cell sorting. The system measures the fluorescent signal intensity of each cell, compares it against predetermined thresholds, and automatically directs sorted cells into appropriate collection tubes, enabling precise isolation of cardiovascular progenitor cells based on their marker expression profiles.
Solution Approach 2:
The patent uses fluorescently labeled antibodies as intermediaries that bind to specific cell surface markers (KDR, C-KIT, CD34) on cardiovascular progenitor cells. These antibody-fluorochrome conjugates serve as mediators that translate the presence of specific markers into detectable fluorescent signals, enabling indirect but highly specific identification and isolation of the target cells.
3Productivity
If multiple growth factors and culture conditions are applied to enrich cardiovascular progenitor cells, then the enrichment and differentiation capability improve, but the culture system complexity increases
Solution Approach 1:
The patent applies growth factors (BMP4, activin A, bFGF, VEGF) and inhibitors (DKK1) at specific time points during embryoid body differentiation to pre-establish the cardiovascular progenitor cell population before isolation. This preliminary biochemical conditioning creates the desired cell population with specific marker expression patterns, simplifying subsequent isolation procedures.
Solution Approach 2:
The patent segments the cardiovascular progenitor cell isolation process into distinct sequential steps: (1) embryoid body formation and differentiation with controlled growth factor exposure, (2) single-cell suspension preparation, (3) fluorescent antibody labeling of cell surface markers, (4) flow cytometric sorting based on marker expression, and (5) collection of enriched progenitor cells. This segmentation allows each step to be optimized independently while maintaining overall process control.
Data Source
AI summary
The present invention provides populations of human cardiovascular progenitor cells, methods of making such cells, and methods of using the cells for production of populations of cardiovascular colonies and populations of cardiomyocytes. Methods of cardiomyocytes replacement therapy are also provided.